Rejecting FDA Advice, ACIP Defers J&J COVID Vaccine Blood Clot Decision Until It Gets More Data

 
• By Derrick Gingery

US FDA suggested potential risk could be managed though a change in the fact sheet, but CDC committee wants more data, which could come within a week or so, to get a better sense of the frequency of the adverse events.

Janssen vaccine and name (shutterstock)
The CDC's advisory committee is hoping a continued pause will allow for better data about the potential risks of Janssen's covid vaccine. • Source: Shutterstock

More from Vaccines

More from Pink Sheet